RU2005115102A - Новые противоопухолевые соединения - Google Patents
Новые противоопухолевые соединения Download PDFInfo
- Publication number
- RU2005115102A RU2005115102A RU2005115102/04A RU2005115102A RU2005115102A RU 2005115102 A RU2005115102 A RU 2005115102A RU 2005115102/04 A RU2005115102/04 A RU 2005115102/04A RU 2005115102 A RU2005115102 A RU 2005115102A RU 2005115102 A RU2005115102 A RU 2005115102A
- Authority
- RU
- Russia
- Prior art keywords
- malignant tumor
- compound
- pharmaceutically acceptable
- malignant
- psoriasis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
Claims (13)
3. Фармацевтическая композиция, содержащая соединение, определяемое в п.1 или 2, и фармацевтически приемлемый носитель, наполнитель или разбавитель.
4. Способ лечения любого млекопитающего, предпочтительно человека, пораженного злокачественной опухолью или псориазом, причем указанный способ включает в себя введение пораженному индивиду терапевтически эффективного количества соединения, определяемого в п.1 или 2.
5. Способ по п.4, где млекопитающим является человек, пораженный злокачественной опухолью.
6. Способ по п.5, при котором пациент поражен стойкой формой злокачественной опухоли, которая не дает благоприятного ответа на другие виды терапии.
7. Способ по п.5, где злокачественная опухоль выбрана из злокачественной опухоли предстательной железы, злокачественной опухоли молочной железы, гепатоклеточной карциномы, меланомы, злокачественной опухоли прямой кишки, злокачественной опухоли почки, злокачественной опухоли яичника, карциномы легких NSCL, злокачественной опухоли эпителия, злокачественной опухоли поджелудочной железы и опухолей, которые экспрессируют в повышенном количестве онкоген Her2/neu.
8. Применение соединения, определяемого в п.1 или 2 в производстве лекарственного средства.
9. Применение соединения, определяемого в п.1 или 2 в производстве лекарственного средства для лечения злокачественной опухоли, псориаза, вирусной инфекции или грибковой инфекции.
10. Набор, включающий в себя отдельные контейнеры, которые содержат фармацевтическую композицию, включающую в себя соединение, определяемое в п.1 или 2, и восстанавливающий агент.
11. Способ получения соединения, определяемого в п.1 или 2.
12. Способ по п.11, отличающийся тем, что в качестве исходного материала используют 4-метилгексановую кислоту.
13. Способ по п.11, отличающийся тем, что в качестве исходного материала используют (4S)-метилгексановую кислоту.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/GB2002/004735 WO2003033012A1 (en) | 2001-10-19 | 2002-10-18 | Kahalalide compounds for use in cancer therapy |
GBPCT/GB02/04735 | 2002-10-18 | ||
GBGB0304367.6A GB0304367D0 (en) | 2003-02-26 | 2003-02-26 | Methods for treating psoriasis |
GB0304367.6 | 2003-02-26 | ||
GB0314725.3 | 2003-06-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2005115102A true RU2005115102A (ru) | 2006-02-27 |
RU2356908C2 RU2356908C2 (ru) | 2009-05-27 |
Family
ID=9953685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2005115102/04A RU2356908C2 (ru) | 2002-10-18 | 2003-10-20 | Новые противоопухолевые соединения |
Country Status (17)
Country | Link |
---|---|
US (2) | US7323444B2 (ru) |
EP (1) | EP1596879B1 (ru) |
JP (1) | JP4800194B2 (ru) |
AT (1) | ATE492285T1 (ru) |
AU (1) | AU2004216443B2 (ru) |
CA (1) | CA2516458C (ru) |
CY (1) | CY1111353T1 (ru) |
DE (1) | DE602004030661D1 (ru) |
DK (1) | DK1596879T3 (ru) |
ES (1) | ES2358018T3 (ru) |
GB (1) | GB0304367D0 (ru) |
MX (1) | MXPA05009029A (ru) |
NZ (1) | NZ541493A (ru) |
PT (1) | PT1596879E (ru) |
RU (1) | RU2356908C2 (ru) |
SI (1) | SI1596879T1 (ru) |
WO (1) | WO2004075910A1 (ru) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0002952D0 (en) * | 2000-02-09 | 2000-03-29 | Pharma Mar Sa | Process for producing kahalalide F compounds |
GB0304367D0 (en) * | 2003-02-26 | 2003-04-02 | Pharma Mar Sau | Methods for treating psoriasis |
US7507708B2 (en) | 2003-02-26 | 2009-03-24 | Pharma Mar, S.A.U. | Antitumoral compounds |
GB0321066D0 (en) * | 2003-09-09 | 2003-10-08 | Pharma Mar Sau | New antitumoral compounds |
CN101861159A (zh) * | 2007-10-19 | 2010-10-13 | 马尔药品公司 | 改进的抗肿瘤治疗 |
JP2011515330A (ja) * | 2008-01-30 | 2011-05-19 | ファルマ・マール・ソシエダード・アノニマ | 改良抗腫瘍治療剤 |
CN101965192A (zh) * | 2008-03-07 | 2011-02-02 | 法马马有限公司 | 改善的抗肿瘤治疗 |
JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
US4943533A (en) * | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
JPS6178719A (ja) * | 1984-09-25 | 1986-04-22 | Tanabe Seiyaku Co Ltd | 総合輸液剤 |
GR870129B (en) * | 1987-01-27 | 1987-02-04 | Giatzidis Ippokratis | Stable bicarbonate - glycylglycine dialysate for hemodialysis and peritoneal dialysis |
US4853388A (en) * | 1987-05-15 | 1989-08-01 | Pearlman Dale L | Method for treating psoriasis with cytotoxic agents |
US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5558864A (en) * | 1991-03-06 | 1996-09-24 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Humanized and chimeric anti-epidermal growth factor receptor monoclonal antibodies |
US5849704A (en) * | 1991-12-20 | 1998-12-15 | Novo Nordisk A/S | Pharmaceutical formulation |
GB9300059D0 (en) * | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
GB9302046D0 (en) | 1993-02-03 | 1993-03-24 | Pharma Mar Sa | Antiumoral compound-v |
US6274551B1 (en) * | 1994-02-03 | 2001-08-14 | Pharmamar, S.A. | Cytotoxic and antiviral compound |
US5932189A (en) * | 1994-07-29 | 1999-08-03 | Diatech, Inc. | Cyclic peptide somatostatin analogs |
US5705511A (en) * | 1994-10-14 | 1998-01-06 | Cephalon, Inc. | Fused pyrrolocarbazoles |
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
JP3927248B2 (ja) | 1995-07-11 | 2007-06-06 | 第一製薬株式会社 | Hgf凍結乾燥製剤 |
ID19609A (id) * | 1996-07-13 | 1998-07-23 | Glaxo Group Ltd | Senyawa-senyawa heterosiklik |
US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
WO1998050406A1 (en) * | 1997-05-09 | 1998-11-12 | The General Hospital Corporation | Cell proliferation related genes |
GB9800569D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9803448D0 (en) | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
US6200598B1 (en) * | 1998-06-18 | 2001-03-13 | Duke University | Temperature-sensitive liposomal formulation |
WO2000031048A1 (en) * | 1998-11-19 | 2000-06-02 | Warner-Lambert Company | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases |
US7311924B2 (en) * | 1999-04-01 | 2007-12-25 | Hana Biosciences, Inc. | Compositions and methods for treating cancer |
UA74803C2 (ru) * | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стойкий полиморф гидрохлорида n-(3-этинилфенил)-6,7-бис(2-метоксиэтокси)-4-хиназолинамина, способ его получения (варианты) и фармацевтическое применение |
GB0002952D0 (en) | 2000-02-09 | 2000-03-29 | Pharma Mar Sa | Process for producing kahalalide F compounds |
JP2004514407A (ja) * | 2000-04-28 | 2004-05-20 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 異種キャプシド中にシュードタイピングされたaav5キャプシドおよびaav5ベクターを含む組換えaavベクター |
US6440465B1 (en) * | 2000-05-01 | 2002-08-27 | Bioderm, Inc. | Topical composition for the treatment of psoriasis and related skin disorders |
KR100834138B1 (ko) * | 2000-10-31 | 2008-06-02 | 파르마 마르, 에스.에이. | 카할라리드 에프 |
US20050054555A1 (en) * | 2001-10-19 | 2005-03-10 | Jose Jimeno | Kahalalide compounds for use in cancer therapy |
WO2003033012A1 (en) | 2001-10-19 | 2003-04-24 | Pharma Mar, S.A. | Kahalalide compounds for use in cancer therapy |
BR0315489A (pt) * | 2002-10-18 | 2005-08-23 | Pharma Mar Sau | Composição antitumorais |
GB0304367D0 (en) * | 2003-02-26 | 2003-04-02 | Pharma Mar Sau | Methods for treating psoriasis |
US7507708B2 (en) * | 2003-02-26 | 2009-03-24 | Pharma Mar, S.A.U. | Antitumoral compounds |
GB0321066D0 (en) | 2003-09-09 | 2003-10-08 | Pharma Mar Sau | New antitumoral compounds |
GB0408958D0 (en) | 2004-04-22 | 2004-05-26 | Pharma Mar Sa | Convergent synthesis for kahalalide compounds |
-
2003
- 2003-02-26 GB GBGB0304367.6A patent/GB0304367D0/en not_active Ceased
- 2003-10-20 RU RU2005115102/04A patent/RU2356908C2/ru not_active IP Right Cessation
-
2004
- 2004-02-26 MX MXPA05009029A patent/MXPA05009029A/es active IP Right Grant
- 2004-02-26 US US10/546,758 patent/US7323444B2/en not_active Expired - Fee Related
- 2004-02-26 PT PT04714847T patent/PT1596879E/pt unknown
- 2004-02-26 EP EP04714847A patent/EP1596879B1/en not_active Expired - Lifetime
- 2004-02-26 DE DE602004030661T patent/DE602004030661D1/de not_active Expired - Lifetime
- 2004-02-26 JP JP2006502323A patent/JP4800194B2/ja not_active Expired - Fee Related
- 2004-02-26 DK DK04714847.3T patent/DK1596879T3/da active
- 2004-02-26 SI SI200431619T patent/SI1596879T1/sl unknown
- 2004-02-26 ES ES04714847T patent/ES2358018T3/es not_active Expired - Lifetime
- 2004-02-26 AU AU2004216443A patent/AU2004216443B2/en not_active Ceased
- 2004-02-26 CA CA2516458A patent/CA2516458C/en not_active Expired - Fee Related
- 2004-02-26 WO PCT/GB2004/000757 patent/WO2004075910A1/en active Application Filing
- 2004-02-26 NZ NZ541493A patent/NZ541493A/en not_active IP Right Cessation
- 2004-02-26 AT AT04714847T patent/ATE492285T1/de active
-
2007
- 2007-12-04 US US11/950,144 patent/US20080090757A1/en not_active Abandoned
-
2011
- 2011-03-22 CY CY20111100314T patent/CY1111353T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
GB0304367D0 (en) | 2003-04-02 |
PT1596879E (pt) | 2011-02-23 |
JP4800194B2 (ja) | 2011-10-26 |
US7323444B2 (en) | 2008-01-29 |
NZ541493A (en) | 2008-07-31 |
ES2358018T3 (es) | 2011-05-04 |
CA2516458C (en) | 2012-11-27 |
ATE492285T1 (de) | 2011-01-15 |
CA2516458A1 (en) | 2004-09-10 |
JP2007527851A (ja) | 2007-10-04 |
AU2004216443B2 (en) | 2009-03-19 |
EP1596879B1 (en) | 2010-12-22 |
US20080090757A1 (en) | 2008-04-17 |
DE602004030661D1 (de) | 2011-02-03 |
AU2004216443A1 (en) | 2004-09-10 |
CY1111353T1 (el) | 2015-08-05 |
DK1596879T3 (da) | 2011-04-11 |
SI1596879T1 (sl) | 2011-07-29 |
WO2004075910A1 (en) | 2004-09-10 |
RU2356908C2 (ru) | 2009-05-27 |
MXPA05009029A (es) | 2005-11-23 |
US20070032412A1 (en) | 2007-02-08 |
EP1596879A1 (en) | 2005-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2468021C2 (ru) | Гетероциклические соединения и их применение | |
ATE219363T1 (de) | Lösliche prodrugs von paclitaxel | |
RU94045155A (ru) | Способы ингибирования болезни альцгеймера | |
BR0212078A (pt) | Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto | |
RU2009117589A (ru) | ПРОИЗВОДНЫЕ ГИДРОБЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ Hsp90 | |
ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
DK0975595T3 (da) | Kokainanaloger | |
RU2006122853A (ru) | Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы | |
RU2007145489A (ru) | Фармацевтические композиции и способы лечения рака и его метастазов | |
NO20054526L (no) | Forebygging og behandling av brystkreft med 4-hydroxy tamoxifen | |
MXPA05007857A (es) | Moduladores derivados de indol de receptores nucleares de hormonas esteroideas. | |
CN108026026A (zh) | 作为化疗剂的β-取代的β-氨基酸和类似物及其应用 | |
HUP0401903A2 (hu) | Az ET-743 továbbfejlesztett alkalmazása daganatok kezelésére | |
RU2003133924A (ru) | Дейтерированные 3-пиперидиноэтилфенилкетоны, а также лекарственные средства, содержащие эти соединения | |
CA2321149A1 (en) | Antitumor agents | |
RU2005115102A (ru) | Новые противоопухолевые соединения | |
IL150817A0 (en) | Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases | |
MX2021015447A (es) | Métodos de tratamiento del cáncer dirigidos a tumores fríos. | |
CA2501089A1 (en) | 4-methylhexanoic kahalaide f compound | |
JP2006517195A5 (ru) | ||
RU2335539C2 (ru) | Фармацевтический препарат и способ лечения злокачественных опухолей у человека с помощью аргининовой депривации | |
TW475897B (en) | A composition for inducing cell of neoplastic cells | |
RU2018114457A (ru) | Лечение syd985 пациентов с t-dm1 рефрактерным раком | |
DE50211672D1 (de) | Urokinase-inhibitoren | |
RU2010118458A (ru) | Производное изоксазола для лечения рака |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20161021 |